ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 9,080,000 shares, a growth of 17.2% from the July 15th total of 7,750,000 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is currently 7.1 days. Approximately 30.5% of the shares of the stock are short sold.
ALX Oncology Stock Down 4.2 %
NASDAQ ALXO traded down $0.11 during trading on Friday, hitting $2.54. The stock had a trading volume of 845,086 shares, compared to its average volume of 821,045. ALX Oncology has a 12 month low of $2.42 and a 12 month high of $17.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. The company’s 50-day moving average price is $5.72 and its two-hundred day moving average price is $11.03. The company has a market capitalization of $132.33 million, a PE ratio of -0.68 and a beta of 1.06.
ALX Oncology (NASDAQ:ALXO – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. As a group, sell-side analysts forecast that ALX Oncology will post -2.89 EPS for the current year.
Analyst Ratings Changes
View Our Latest Stock Report on ALX Oncology
Insider Activity at ALX Oncology
In related news, CFO Peter S. Garcia purchased 12,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was acquired at an average price of $8.53 per share, with a total value of $102,360.00. Following the completion of the acquisition, the chief financial officer now directly owns 122,348 shares in the company, valued at approximately $1,043,628.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ALX Oncology news, CFO Peter S. Garcia purchased 12,000 shares of the stock in a transaction dated Thursday, June 13th. The stock was bought at an average price of $8.53 per share, for a total transaction of $102,360.00. Following the transaction, the chief financial officer now directly owns 122,348 shares in the company, valued at $1,043,628.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the transaction, the insider now directly owns 593,447 shares in the company, valued at $4,688,231.30. The disclosure for this sale can be found here. Insiders sold 48,398 shares of company stock valued at $368,643 in the last three months. Corporate insiders own 33.40% of the company’s stock.
Hedge Funds Weigh In On ALX Oncology
Large investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of ALX Oncology in the fourth quarter valued at about $28,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of ALX Oncology during the 1st quarter worth approximately $27,000. EntryPoint Capital LLC acquired a new stake in shares of ALX Oncology in the 1st quarter valued at approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in ALX Oncology by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after buying an additional 3,825 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Read More
- Five stocks we like better than ALX Oncology
- How to Most Effectively Use the MarketBeat Earnings Screener
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Using the MarketBeat Dividend Yield Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.